Atara Biotherap's average rating is Strong Buy from 5 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Atara Biotherap market sentiment investors' perception of the future value of Atara. Let us look at a few aspects of Atara technical analysis.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Atara Biotherapeutics. In general, sophisticated investors focus on analyzing Atara Biotherapeutics stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Atara Biotherapeutics's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of Atara Biotherapeutics's intrinsic value. In addition to deriving basic predictive indicators for Atara Biotherapeutics, many experienced traders also check how macroeconomic factors affect Atara Biotherapeutics price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of Atara Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Atara Biotherapeutics. Your research has to be compared to or analyzed against Atara Biotherapeutics' peers to derive any actionable benefits. When done correctly, Atara Biotherapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Atara Biotherapeutics.
Watch out for price decline
Please consider monitoring Atara Biotherapeutics on a daily basis if you are holding a position in it. Atara Biotherapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Atara Biotherapeutics stock to be traded above the $1 level to remain listed. If Atara Biotherapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How does Atara Stands against Peers?
Analyzing Atara Biotherapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Atara Biotherapeutics across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
Atara Biotherapeutics Competition DetailsAtara Biotherapeutics Gross Profit
Atara Biotherapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Atara Biotherapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Atara Biotherapeutics Gross Profit growth over the last 10 years. Please check Atara Biotherapeutics'
gross profit and other
fundamental indicators for more details.
Closer look at Atara Biotherap Variance
Atara Biotherap has current Variance of 15.44. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.
Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.
Variance | = | SUM(RET DEV)2 N |
| = | 15.44 |
| SUM | = | Summation notation |
| RET DEV | = | Actual returns deviation over selected period |
| N | = | Number of points for the period |
Are Atara Biotherap technical ratios showing a come-back?
The coefficient of variation is down to 3437.22 as of today. Atara Biotherap shows above-average downside volatility for the selected time horizon. We advise investors to inspect Atara Biotherap further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Atara Biotherap future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Atara Biotherap's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Atara Biotherap's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Atara Biotherap Implied Volatility
Atara Biotherap's implied volatility exposes the market's sentiment of Atara Biotherap stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Atara Biotherap's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Atara Biotherap stock will not fluctuate a lot when Atara Biotherap's options are near their expiration.
The Current Takeaway on Atara Biotherap Investment
Whereas some companies under the biotechnology industry are still a bit expensive, Atara Biotherap may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Atara Biotherap.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Atara Biotherapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com